FDA Approves New Manufacturing Process for Alvotech's SIMLANDI® Biosimilar, Doubling Output

Alvotech has received FDA approval for a new manufacturing process for its biosimilar SIMLANDI® (adalimumab-ryvk), which more than doubles the drug substance output per batch. This enhancement increases manufacturing productivity and frees up capacity, supporting the growing demand across Alvotech's biosimilars portfolio.